The gynecologic cancer models used in this study express various p53 mutants and differ by HRR status, which makes them useful for assessing the activity of p53 reactivators and PARP inhibitors [[30], [31], [32]] (Fig. 1A). The gene discussed is TP53; the disease is female reproductive organ cancer.